BOULDER, Colo.--(BUSINESS WIRE)--OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced the appointment of Nicholas A. Saccomano, Ph.D., to its Board of Directors. Dr. Saccomano is a seasoned biopharmaceutical professional with nearly 35 years of extensive research and development experience across multiple therapeutic areas, including oncology.
“We are thrilled to welcome Nicholas to the Board, as his track record of successfully guiding drug discovery programs from idea to registration will bring invaluable perspective to OnKure,” said Tony Piscopio, Ph.D., Co-Founder, President and Chief Executive Officer of OnKure. “Having made significant contributions to the success of Array Biopharma, Nicholas is extremely familiar with our proven structure-based drug development approach, and we look forward to his strategic insights as we continue to advance and expand our extensive oncology pipeline.”
Previously, Dr. Saccomano worked at Pfizer R&D, Inc. as Chief Science Officer and Site Head at its Boulder facility, where he led a 170-person research and development team that advanced a portfolio of small molecule drug programs from inception to proof-of-concept. Prior to working at Pfizer, Dr. Saccomano served as Chief Science Officer at Array Biopharma Inc., where he was responsible for creating and advancing ten clinical-stage compounds, with seven drug approvals to date. Dr. Saccomano also served as Chief Technology Officer at SomaLogic Inc., where he managed scientific and technical teams in charge of advancing elements of the company’s proteomic platform. He currently serves as a scientific advisor to several innovative life sciences companies. Dr. Saccomano received a B.S. from the State University of New York at Buffalo and a Ph.D. in Organic Chemistry from Columbia University under the direction of Gilbert Stork.
“Developing life-saving therapeutics has been a passion of mine throughout my career, and I truly believe OnKure has the potential to discover the next generation of precision medicines,” said Dr. Saccomano. “I look forward to collaborating with the Board and management team as we work together to successfully advance OnKure’s differentiated programs through the clinic.”
About OnKure Therapeutics
OnKure, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer. Using its proven structure-based drug design approach, the Company is building a robust pipeline of tumor-agnostic candidates that are designed to achieve optimal tolerability and efficacy. OnKure is currently developing its lead clinical candidate, OKI-179, an oral, selective Class 1 HDAC inhibitor, for the treatment of both hematological and solid tumors, with plans to initiate a Phase 2 combination trial with binimetinib in NRAS melanoma in 2022.
For more information, please visit www.onkuretherapeutics.com and follow us on LinkedIn and Twitter.
